Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-08-17 00:00:00 ET · period of report 2022-08-15 · accession 0000899243-22-029030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-08-17 | 2022-08-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $303.93 | -22.2K | 61.6K | -26% | -$6.74M |
| D | 2022-08-17 | 2022-08-15 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $155.57 | +6,571 | 67.5K | +11% | +$1.02M |
| D | 2022-08-17 | 2022-08-15 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $0.00 | -6,571 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-15 | S | D | 4,242 | $301.61 | 61,955 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $301.61 (range $301.09 to $302.01). |
| 2 | Common | Common Stock | 2022-08-15 | S | D | 2,339 | $303.78 | 59,216 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F6) Open market sales reported on this line occurred at a weighted average price of $303.78 (range $303.13 to $304.09). |
| 3 | Common | Common Stock | 2022-08-15 | S | D | 6,990 | $304.67 | 52,226 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F7) Open market sales reported on this line occurred at a weighted average price of $304.67 (range $304.13 to $305.12). |
| 4 | Common | Common Stock | 2022-08-15 | S | D | 6,948 | $305.38 | 45,278 | D | — | — | (F8) Open market sales reported on this line occurred at a weighted average price of $305.38 (range $305.13 to $305.83). (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. |
| 5 | Common | Common Stock | 2022-08-15 | S | D | 1,254 | $300.30 | 66,197 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F3) Open market sales reported on this line occurred at a weighted average price of $300.30 (range $300.00 to $300.73). |
| 6 | Common | Common Stock | 2022-08-15 | M | A | 6,571 | $155.57 | 67,451 | D | — | — | |
| 7 | Common | Common Stock | 2022-08-15 | S | D | 400 | $302.55 | 61,555 | D | — | — | (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price. (F5) Open market sales reported on this line occurred at a weighted average price of $302.55 (range $302.13 to $302.90). |
| 8 | Derivative | Stock Option (Right to Buy) | 2022-08-15 | M | D | 6,571 | $0.00 | 0 | D | $155.57 · — to 2028-02-05 | 6,571 Common Stock | (F9) Fully vested. |